Information from Orphazyme A/S about the Clinical Development of Arimoclomol in sIBM during the COVID-19 Pandemic
Patients with sporadic inclusion body myositis (sIBM), together with their care partners, have been asking questions about the clinical trial of Arimoclomol during the COVID-19 pandemic. Inclusion body myositis has no approved therapies and there is substantial interest in this clinical trial. In the myositis community, we are following it closely.
Participants in the trial have been wondering how they will be protected during social isolation/distancing while also meeting their required clinical trial healthcare visits and testing, and about how COVID-19 impacts the trial overall.
We have been in regular contact with the amazing team at Orphazyme and we are happy to provide you with a statement that addresses some of these important questions.
We thank Orphazyme, a sponsor of MSU, for their commitment to keeping us informed and safe.
Tags: clinical trials inclusion body myositis sibm